PapersFlow Research Brief
CAR-T cell therapy research
Research Guide
What is CAR-T cell therapy research?
CAR-T cell therapy research encompasses studies on chimeric antigen receptor (CAR) T cell therapy, an immunotherapy method that engineers patient T cells to express CARs for specific targeting and destruction of cancer cells, particularly in leukemia, lymphoma, and solid tumors.
CAR-T cell therapy research includes 78,250 works focused on genetically modifying T cells to attack cancer through adoptive cell transfer. Papers examine applications in leukemia and lymphoma alongside management of cytokine release syndrome. Research also assesses long-term efficacy and safety profiles of CAR-T treatments.
Topic Hierarchy
Research Sub-Topics
CAR-T Cell Therapy for Hematologic Malignancies
This sub-topic focuses on clinical applications and outcomes of CAR-T therapies targeting CD19 in leukemias and lymphomas. Researchers study response rates, relapse mechanisms, and consolidation strategies.
CAR-T Therapy for Solid Tumors
This sub-topic addresses challenges like tumor microenvironment inhibition and antigen heterogeneity in solid tumor CAR-T applications. Researchers engineer next-generation CARs for enhanced infiltration and persistence.
Cytokine Release Syndrome Management
This sub-topic examines pathophysiology, grading, and therapeutic interventions like tocilizumab for CRS in CAR-T patients. Researchers develop predictive biomarkers and preventive strategies.
CAR Construct Design and Optimization
This sub-topic covers engineering of CAR generations, including hinge domains, costimulatory signals, and logic-gated designs. Researchers optimize for efficacy, safety, and manufacturing.
Long-term Outcomes and Persistence of CAR-T
This sub-topic investigates durable remissions, memory T cell phenotypes, and late toxicities in long-term CAR-T survivors. Researchers track real-world data and predictors of sustained responses.
Why It Matters
CAR-T cell therapy research supports immunotherapy advancements by detailing T cell engineering for precise cancer cell targeting, with implications for treating leukemia, lymphoma, and solid tumors. Related immune checkpoint studies demonstrate clinical benefits, such as PD-1/PD-L1 blockade yielding objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer (Topalian et al., 2012, "Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer"). Anti-PD-L1 antibody treatments induced durable tumor regression with objective response rates of 6 to 17% and disease stabilization rates of 12 to 41% at 24 weeks in advanced cancers including non-small-cell lung cancer, melanoma, and renal-cell cancer (Brahmer et al., 2012, "Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer"). These findings from highly cited papers inform CAR-T combination strategies and toxicity management like cytokine release syndrome.
Reading Guide
Where to Start
"The blockade of immune checkpoints in cancer immunotherapy" (Pardoll, 2012) provides foundational mechanisms of T cell activation relevant to CAR-T engineering, making it accessible for understanding immunotherapy basics before diving into CAR specifics.
Key Papers Explained
Pardoll (2012) "The blockade of immune checkpoints in cancer immunotherapy" establishes immune evasion principles that Topalian et al. (2012) "Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer" tests clinically, showing PD-1 blockade responses tied to PD-L1 expression; Hodi et al. (2010) "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" extends to CTLA-4 inhibition with survival gains; Brahmer et al. (2012) "Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer" confirms PD-L1 targeting efficacy, collectively informing CAR-T enhancement strategies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current CAR-T research builds on checkpoint blockade integration for solid tumors, addressing cytokine release syndrome, with no recent preprints or news available to indicate active frontiers.
Papers at a Glance
Frequently Asked Questions
What is CAR-T cell therapy?
CAR-T cell therapy is an immunotherapy that genetically engineers patient T cells to express chimeric antigen receptors targeting cancer cells. It applies to leukemia, lymphoma, and solid tumors. Research covers cytokine release syndrome management and long-term safety.
How does immune checkpoint blockade relate to CAR-T research?
Immune checkpoint blockade, such as PD-1/PD-L1 inhibition, complements CAR-T by enhancing T cell antitumor activity. Pardoll (2012) in "The blockade of immune checkpoints in cancer immunotherapy" outlines mechanisms supporting adoptive T cell therapies. This integration addresses adaptive immune resistance in tumors.
What are key side effects in CAR-T therapy?
Cytokine release syndrome is a primary side effect managed in CAR-T research. Ipilimumab trials showed severe, long-lasting, but mostly reversible adverse events (Hodi et al., 2010, "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma"). Similar profiles appear in PD-1 blockade studies.
What cancers does CAR-T target?
CAR-T targets leukemia, lymphoma, and solid tumors via engineered T cells. Checkpoint inhibitors extend to breast cancer (Hartkopf et al., 2016, "PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer"), melanoma, and renal-cell cancer. Efficacy includes tumor regression through adoptive transfer.
What is the current scale of CAR-T research?
CAR-T cell therapy research comprises 78,250 papers. Growth data over five years is unavailable. Keywords include CAR T Cells, Chimeric Antigen Receptor, and Cancer Immunotherapy.
How do regulatory T cells factor into CAR-T?
Regulatory T cells maintain self-tolerance via Foxp3 transcription factor (Hori et al., 2003, "Control of Regulatory T Cell Development by the Transcription Factor Foxp3"). CAR-T research considers their suppression to boost antitumor responses. This aids therapy optimization.
Open Research Questions
- ? How can CAR-T therapies minimize cytokine release syndrome while preserving efficacy against solid tumors?
- ? What role does PD-L1 expression on tumors play in optimizing CAR-T cell persistence?
- ? How do Foxp3+ regulatory T cells interact with CAR-T engineered cells in immunosuppressive microenvironments?
- ? Which combinations of CAR-T with PD-1/CTLA-4 blockade yield durable responses in lymphoma?
- ? What tools like TIMER reveal about tumor-infiltrating immune cells in CAR-T treated patients?
Recent Trends
CAR-T cell therapy research totals 78,250 papers with five-year growth data unavailable.
Highly cited works emphasize immune checkpoint roles, such as PD-1/PD-L1 inhibitors achieving 6-17% response rates (Brahmer et al., 2012) and ipilimumab improving survival in melanoma (Hodi et al., 2010).
No recent preprints or news coverage in the last 12 months reported.
Research CAR-T cell therapy research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CAR-T cell therapy research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers